PURPOSE: Randomised trials have shown that empiric ICD programming, using long detection times and high detection zones, reduces device therapy in ICD recipients. However, there is less data on its effectiveness in a "real-world" setting, especially secondary prevention patients. Our aim was to evaluate the introduction of a standardised programming protocol in a real-world setting of unselected ICD recipients. METHODS: We analysed 270 consecutive ICD recipients implanted in a single centre-135 implanted prior to protocol implementation (physician-led group) and 135 after (standardised group). The protocol included long arrhythmia detection times (30/40 or equivalent) and high rate detection zones (primary prevention lower treatment zone 200 bpm). Programming in the physician-led group was at the discretion of the implanter. The primary endpoint was time-to-any therapy (ATP or shocks). Secondary endpoints were time-to-inappropriate therapy and time-to-appropriate therapy. The safety endpoints were syncopal episodes, hospital admissions and death. RESULTS: At 12 months follow-up, 47 patients had received any ICD therapy (physician-led group, n = 31 vs. standardised group, n = 16). There was a 47 % risk reduction in any device therapy (p = 0.04) and an 86 % risk reduction in inappropriate therapy (p = 0.009) in the standardised compared to the physician-led group. There was a non-significant 30 % risk reduction in appropriate therapy (p = 0.32). Results were consistent across primary and secondary prevention patients. There were no significant differences in the rates of syncope, hospitalisation, and death. CONCLUSIONS: In unselected patients in a real-world setting, introduction of a standardised programming protocol, using long detection times and high detection zones, significantly reduces the burden of ICD therapy without an increase in adverse outcomes.
PURPOSE: Randomised trials have shown that empiric ICD programming, using long detection times and high detection zones, reduces device therapy in ICD recipients. However, there is less data on its effectiveness in a "real-world" setting, especially secondary prevention patients. Our aim was to evaluate the introduction of a standardised programming protocol in a real-world setting of unselected ICD recipients. METHODS: We analysed 270 consecutive ICD recipients implanted in a single centre-135 implanted prior to protocol implementation (physician-led group) and 135 after (standardised group). The protocol included long arrhythmia detection times (30/40 or equivalent) and high rate detection zones (primary prevention lower treatment zone 200 bpm). Programming in the physician-led group was at the discretion of the implanter. The primary endpoint was time-to-any therapy (ATP or shocks). Secondary endpoints were time-to-inappropriate therapy and time-to-appropriate therapy. The safety endpoints were syncopal episodes, hospital admissions and death. RESULTS: At 12 months follow-up, 47 patients had received any ICD therapy (physician-led group, n = 31 vs. standardised group, n = 16). There was a 47 % risk reduction in any device therapy (p = 0.04) and an 86 % risk reduction in inappropriate therapy (p = 0.009) in the standardised compared to the physician-led group. There was a non-significant 30 % risk reduction in appropriate therapy (p = 0.32). Results were consistent across primary and secondary prevention patients. There were no significant differences in the rates of syncope, hospitalisation, and death. CONCLUSIONS: In unselected patients in a real-world setting, introduction of a standardised programming protocol, using long detection times and high detection zones, significantly reduces the burden of ICD therapy without an increase in adverse outcomes.
Entities:
Keywords:
High detection rate; Implantable cardioverter defibrillator; Inappropriate therapy; Long detection time; Shocks
Authors: Avi Fischer; Kevin T Ousdigian; James W Johnson; Jeffrey M Gillberg; Bruce L Wilkoff Journal: Heart Rhythm Date: 2011-08-09 Impact factor: 6.343
Authors: Maurizio Gasparini; Alessandro Proclemer; Catherine Klersy; Axel Kloppe; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijfels; Elisabetta Santi; Laura Manotta; Angel Arenal Journal: JAMA Date: 2013-05-08 Impact factor: 56.272
Authors: Eleanor B Schron; Derek V Exner; Qing Yao; Louise S Jenkins; Jonathan S Steinberg; James R Cook; Steven P Kutalek; Peter L Friedman; Rosemary S Bubien; Richard L Page; Judy Powell Journal: Circulation Date: 2002-02-05 Impact factor: 29.690
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: Marc T Silver; Laurence D Sterns; Jonathan P Piccini; Boyoung Joung; Chi-Keong Ching; Robert A Pickett; Rafael Rabinovich; Shufeng Liu; Brett J Peterson; Daniel R Lexcen Journal: Heart Rhythm Date: 2014-11-07 Impact factor: 6.343
Authors: Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: Jonathan Buber; David Luria; Osnat Gurevitz; David Bar-Lev; Michael Eldar; Michael Glikson Journal: Europace Date: 2013-10-09 Impact factor: 5.214
Authors: Axel Kloppe; Alessandro Proclemer; Angel Arenal; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijffels; Elisabetta Santi; Laura Manotta; Lorenza Mangoni; Maurizio Gasparini Journal: Circulation Date: 2014-05-16 Impact factor: 29.690